This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Influenza virus	Influenza A virus hemagglutinin (HA)	<p><i>In vitro</i> and mouse studies suggest a broadly neutralizing antibody against influenza A virus HA could help treat or prevent influenza infection. <i>In vitro</i>, the mAb F16, isolated from an individual vaccinated against influenza, bound all 16 subtypes of influenza A virus HA and neutralized multiple group 1 and group 2 influenza A viruses. In mouse and ferret models of H1N1, H3N2 or H5N1 viral infection, F16 given before or after viral challenge decreased morbidity and mortality compared with an unrelated control mAb. Humabs BioMed S.A. has F16 in ongoing preclinical testing to prevent or treat influenza infection.</p> <p>Flu-mAb, a universal mAb product that includes broadly neutralizing antibodies against group 1 and group 2 influenza virus from Johnson & Johnson, is in preclinical testing to treat and prevent influenza A viral infections.</p> <p>SciBX 4(30); doi:10.1038/scibx.2011.855 Published online Aug. 4, 2011</p>	Patented by the Institute for Research in Biomedicine; licensed to Humabs BioMed	<p>Corti, D. <i>et al. Science</i>; published online July 28, 2011; doi:10.1126/science.1205669</p> <p>Contact: Antonio Lanzavecchia, Institute for Research in Biomedicine, Bellinzona, Switzerland e-mail: lanzavecchia@irb.unisi.ch</p> <p>Contact: John J. Skehel, National Institute for Medical Research, London, U.K. e-mail: skeheljj@nimr.mrc.ac</p>